Streptococcus pyogenes (group A Streptococcus) has reemerged in recent years as a cause of severe human disease. Because extracellular products are involved in streptococcal pathogenesis, we explored the possibility that a disease isolate expresses an uncharacterized superantigen. We screened culture supernatants for superantigen activity with a major histocompatibility complex class II-dependent T cell proliferation assay. Initial fractionation with red dye A chromatography indicated production of a class II-dependent T cell mitogen by a toxic shock-like syndrome (TSLS) strain. The amino terminus of the purified streptococcal superantigen was more homologous to the amino termini of staphylococcal enterotoxins B, C1, and C3 (SEB, SEC,, and SEC3), than to those of pyrogenic exotoxins A, B, C or other streptococcal toxins. The molecule, designated SSA, had the same pattern of class II isotype usage as SEB in T cell proliferation assays. However, it differed in its pattern of human T cell activation, as measured by quantitative polymerase chain reaction with Va-specific primers. SSA activated human T cells that express V#1, 3, 15 with a minor increase of V#5.2-bearing cells, whereas SEB activated V,63, 12, 15, and 17-bearing T cells. Immunoblot analysis of 75 disease isolates from several localities detected SSA production only in group A streptococci, and found that SSA is apparently confined to only three clonal lineages as defined by multilocus enzyme electrophoresis typing. Isolates of one of these lineages, (electrophoretic type 2) are strongly associated with TSLS. The data identify SSA as a novel streptococcal superantigen that appears to be more related structurally to staphylococcal enterotoxins than to streptococcal exotoxins. Because abundant SSA production is apparently confined to only three streptococcal clonal lineages, the data also suggest that the SSA gene has only recently been acquired by S. pyogenes. (J. Clin.
Introduction
In recent years, the United States has experienced a resurgence of severe, streptococcal infections, including toxic shock-like syndrome (TSLS) I and acute rheumatic fever (1) (2) (3) . Although the occurrence of several streptococcal virulence factors has been examined, no streptococcal molecule has been implicated as the sole cause of these diseases, a finding that presumably reflects the involvement of multiple bacterial products.
Bacterial superantigens, characteristically produced by Gram-positive cocci such as Staphylococcus aureus and Streptococcuspyogenes, may play a central role in disease pathogenesis. Superantigens are mitogens that activate T cells in a specific manner. These proteins bind to MHC class II molecules and activate T cells bearing one or few types ofvariable segments in their T cell receptor (TCR) ,3 chain (4) (5) (6) (7) (8) . By virtue of this mechanism, 1-5% of peripheral T cells potentially respond to individual toxins. It has been proposed that several streptococcal and staphylococcal toxin-mediated diseases are caused, at least in part, by release of T cell cytokines (9, 10) .
S. pyogenes produces several extracellular virulence factors that include pyrogenic exotoxins A, B, and C (SPE-A, B, and C), and evidence exists that SPE-A and SPE-C are superantigens (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . There is controversy about the assignment of superantigen status to SPE-B, a protein that may be an allele of streptococcal cysteine proteinase (SP) ( 14) . A large percentage of S. pyogenes strains from patients with severe invasive infections produce SPE-A (scarlet fever toxin) and it is probable that SPE-A is involved in the pathogenesis ofmany TSLS cases (3, 15) . However, because the molecular mechanism of severe streptococcal diseases is not fully understood, we examined pathogenic strains for ability to express additional superantigens.
In this article we describe isolation and characterization ofa novel streptococcal superantigen from two group A streptococcal strains that caused TSLS. Interestingly, this new molecule exhibits striking NH2-terminal sequence homology to staphylococcal enterotoxin B, C,, and C3 (SEB, SEC,, and SEC3) rather than to characterized streptococcal products. Expression ofthis molecule by one of the two streptococcal clones that cause the majority of severe streptococcal disease in adult humans suggests that this superantigen may be a virulence factor in streptococcal diseases.
Methods
Bacterial strains. During the initial phase of this study, SSA was obtained from group A streptococcal strain Weller (serotype M3). This organism and strain Gall (serotype Ml) were recovered from patients with fatal TSLS and were provided by Dennis L. Stevens, Veterans Affairs Hospital, Boise, ID. These strains also carry the designations DLS88002 (Weller) and DLS89026 (Gall) and both produce SPE-A (Dennis L. Stevens, personal communication). In the course of our investigation, we identified a second strain, MGAS 158 (15) , that pro-duced higher levels of SSA than strain Weller. The purification strategy developed for Weller supernatants was applied to strain MGAS 158 with similar resulting purification of SSA. Additional organisms used in this study included 58 strains ofS. pyogenes recovered from patients with contemporary episodes of invasive disease and TSLS ( 15) Todd-Hewitt broth were inoculated with 150 ml of an overnight culture ofstrain MGAS 158. Chemically defined media broth consisted of 27.1 g/liter chemically defined media (JRH Biosciences, Lenexa, KS) supplemented with 2.5 g/liter sodium bicarbonate and 0.5 g/liter Lcysteine. Components were mixed in water at room temperature, supplemented with Todd-Hewitt broth, and filtered (0.45 ,m). Stationary cultures were incubated at 37°C in a humidified environment supplemented with 5% CO2 for 24 h and harvested by centrifugation. The supernatant was filtered (0.45 ,m) and sodium azide (0.05% wt/vol) was added. Supernatants were concentrated to -50 ml at 4°C on YM10 (10-kD cutoff) membranes (Amicon Corp., Danvers, MA). The material was dialyzed against a total of 12 liters of 20 mM sodium phosphate buffer, pH 6.8, for -24 h. The dialyzate was again filtered (0.45 gm) and supplemented with sodium azide.
A red dye A (RDA) (Amicon Corp.) column ( 1.5 X 20 cm, 30-ml bed volume) was prepared by stripping the matrix with three column volumes of 8 M urea in 0.5 M NaOH, and the column was equilibrated with 20 mM sodium phosphate buffer, pH 6.8. The concentrated supernatant was passed through this column twice at a flow rate of 18 ml/h at room temperature and the column was washed to background absorbance (280 nm) with 20 mM sodium phosphate buffer. The column was eluted with two column volumes each ofa step gradient of60, 150, 300, and 500 mM sodium phosphate, pH 6.8, and the elution profile was monitored with an A28 UV detector. Fractions ( 12 ml) were collected and assayed for class II-dependent T cell mitogenic activity (7). Active fractions were pooled and concentrated to 3 ml using a Centriprep and Centricon 10 concentrators (Amicon Corp.). The material was buffer exchanged into PBS using a DG-10 column (Bio-Rad Laboratories, Richmond, CA) and passed twice over an anti-SSA IgG conjugated Sepharose column (3-ml bed volume). The anti-SSA IgG was conjugated at a concentration of 4 mg IgG/ml Sepharose using a directional coupling system (Affinica, Schleicher & Schuell, Inc., Keene, NH). The column was washed to background absorbance (A280) using PBS and eluted with 0.1 M sodium acetate and 0. (19) and PCR was performed as described previously (20) . Specific Vf oligonucleotide primers were kindly provided by Dr. Michael Brenner (Harvard University, Cambridge, MA) and had the same coding sequences as previously described (20) but included an added SalI cleavage site at the 5' end. The 3' primers were labeled using polynucleotide kinase (New England Biolabs, Beverly, MA) and [y-32P]ATP. First strand template was combined with the Ca and CB primers, Taq polymerase, nucleotides and buffer, and aliquots were transferred to each of 22 tubes containing the Vf3-specific oligonucleotide primers. Amplification was carried out for 25 cycles at 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min. 10 ,l of the reaction mixture were electrophoresed in a 2% agarose gel, and the gels were dried and autoradiographed. The autoradiograms were analyzed with adensitometer(model EC9 10, E-CApparatus Corp., St. Petersburg, FL) and the areas under the curves were derived with the GS370 Electrophoresis Data system program (Hoefer Scientific Instruments, San Francisco, CA). The data are presented as the ratio of the area of the V1 product to the area of the Ca product.
Determination of class II isotype usage. Twofold dilutions of partially purified SSA were incubated with highly purified T cells (6 x 104 per well) and L cells (3 x 104 per well) transfected with the genes encoding DR4 (L165.1), DQ7a/3# (L54), DP4 (L25.1), I-Ed(RT 10.3B-C1), I-Ad(RT 2.3.3H-D6), or the neomycin resistance gene only (L66), as previously described (7). Cultures were incubated in flat-bottom 96-well plates for 90 h and labeled with 1 MCi of [3H]-thymidine for the final 18 h.
Immunoblot detection ofSSA. Streptococcal organisms were grown for 24 h in chemically defined media/2% Todd-Hewitt broth, and supernatants harvested by centrifugation and filtration (0.45 ,m). Supernatant samples (3 ml) were precipitated by addition of 4 vol of ethanol and centrifuged at 16,000g. The precipitate was solubilized in 300 ,l of SDS buffer plus 2-mercaptoethanol, boiled for 5 min and centrifuged at 14,000 g for 10 min to remove precipitate. Samples (50 ul) were electrophoresed through a 10% SDS-PAGE gel (120 X 160 X 1.5 mm). Gels were blotted to Hybond C (Amersham Corp., Arlington Heights, IL) at 30 V for 10 h and 50 V for the final 2 h in Towbin transfer buffer (21) . The blots were dried, blocked for 2 h in PBS/2% BSA at 25°C and washed extensively. Duplicate blots were probed overnight at 4°C with anti-SSA-Ig conjugated directly to horseradish peroxidase in the presence of 100 Mg/ml of either the immunizing peptide, SSA (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , or a control peptide from ragweed allergen, Ra3 (54-67) peptide, (22) . The blots were developed with the ECL chemiluminescence detection system (Amersham Corp.).
Results
Purification of SSA from S. pyogenes strain Weller. Because RDA has been used to purify several staphylococcal enterotoxNovel Superantigenfrom Streptococcus pyogenes 711 ins (23, 24) , we thought this material might be useful in identifying novel S. pyogenes superantigens. Concentrated culture supernatants from strain Weller were chromatographed on a RDA column, the column was eluted with a phosphate step gradient, and fractions were tested for the presence of a class II-dependent T cell mitogen (7) . We identified such an activity eluting between 60 and 150 mM P04, corresponding approximately to fraction numbers 8-55 (Fig. 1 ). This activity eluted in a broad peak and did not correspond to a detectable protein peak. Examination of an aliquot of the pooled activity by SDS-PAGE gel revealed many proteins, some in the 30-kD range (data not shown). We then fractionated the pooled active fractions from the RDA column by gel filtration (G-75) and anion exchange chromatography and selected active fractions from each column. The product from the final chromatography step consisted predominantly of three proteins (Fig. 2  A) . The proteins were blotted to a solid support and analyzed by NH2-terminal sequencing. The higher M, protein was identified as SP and/or SPE-B ( 14) . These two proteins are closely similar and cannot be distinguished based on the 29 amino acids sequenced. The lower Mr protein, -27 kD in size, yielded a 59-amino acid NH2 terminus that was not notably homologous to any previously characterized protein. The middle band (28 kD) displayed an NH2 terminus strikingly similar to the NH2 termini of SEB, SEC1, and SEC3 and dissimilar to M protein (Fig. 3) . The 28-kD molecule with the SEB-like NH2 terminus was designated SSA.
Purification ofSSA by Ab affinity chromatography. To determine whether or not SSA was responsible for the superantigen activity, we focused our efforts on its purification. An antipeptide antiserum was raised against the first 19 amino acids of SSA. To determine the ability of the anti-SSA Abs to bind native SSA, a concentrated streptococcal supernatant from 16 liters was chromatographed on RDA in an effort to enrich for SSA. The RDA eluate was passed over the anti-SSA Ab column and the column eluted. Examination of the eluate by SDS-PAGE gel, and silver stain identified one prominent band at 28 kD, and two minor bands, one at 25 kD and one at -12 kD (Fig. 2 B, lane 1) . NH2-terminal sequencing of the 28-kD product identified the SSA NH2 amino terminus shown in Fig. 3 . To determine whether the lower M, species were contaminants or SSA degradation products, we subjected an identical sample to immunoblot analysis. Anti-SSA antibodies detected all three species shown in the silver stain gel, indicating that these lower molecular weight bands were breakdown products of the 28-kD protein. Because the antibodies were directed against the NH2 terminus, these products likely represent SSA molecules missing COOH terminal sections.
To test whether SSA had superantigen activity, we examined the ability ofSSA to stimulate T cell proliferation in a class II-dependent fashion. Purified SSA (identical to that shown in Fig. 2 B) displayed potent mitogenic activity that was entirely dependent on the presence of MHC class II molecules (Fig. 4 ). These data demonstrate that class II-dependent T cell proliferative activity can be assigned to the SSA molecule and is not due to some contaminating protein such as SPE-A, SPE-B, or M protein.
SSA and SEB have similar MHC class II isotype specificity. Some superantigens exhibit variable patterns with respect to the MHC class II isotypes to which they bind (25, 26 HLA-DP or H-2 I-A (HLA tranfectants, Fig. 5 A and H-2 transfectants, Fig. 5 B) , a usage pattern similar to that exhibited by SEB (25, 27) . From these data we conclude that like SEB, SSA has a "restricted" ability to utilize MHC class II isotypes.
SSA has a unique pattern ofhuman Vf3-specific T cell acti- Hence, the Vfl specificities of SSA and SEB are virtually distinct, and importantly, the V(3 specificity of SSA is unique compared to related enterotoxins and the pyrogenic exotoxins (Table I ). In addition, SSA is the only bacterial superantigen known to activate human V31.
SPE-A and SSA are antigenically distinct molecules. Four alleles of SPE-A have been described to date (28) . Because recent work from our laboratory showed that the sites on SEA and SEE that mediate class II-and TCR binding activities localize to discrete domains in the NH2-and COOH-terminal regions, respectively, it is a formal possibility that SSA is an allelic variant of SPE-A that has acquired new class II binding and Vfl-specificities through mutations of relatively few amino acids. Thus, past amino acid 24, SSA may begin to show more homology to SPE-A. We therefore probed SSA and SPE-A with antisera against the two proteins to look for antigenic relatedness. Anti-SPE-A antisera strongly detected SPE-A, but showed very little cross reactivity with SSA (Fig. 7) . If SSA resembles SEB throughout the molecules, as its NH2 terminus suggests, then a small amount ofcross-reactivity between anti-SPE-A and SSA might be expected base on previous studies (29) . A duplicate blot was also probed with anti-SSA and showed that anti-SSA does not detect SPE-A. This blot is not as informative as the reciprocal experiment because the anti-SSA Abs used were raised against the amino-terminal 19 amino acids of SSA and thus can only give information about the immunological relatedness of the extreme NH2 termini of these two proteins. The strongest evidence that SSA and SPE-A are not allelic variants is the fact that SSA is produced by many strains that lack the speA gene (Table II) .
Restriction ofSSA production to S. pyogenes. To determine whether production of SSA is restricted to group A streptococci, eight strains of Lancefield group B, five strains of group C and three strains of group G streptococci were screened by immunoblot assay. We failed to identify evidence of SSA production by the non-group A streptococcal strains tested (data not shown), suggesting that expression is restricted to S. pyogenes.
Expression ofSSA by pathogenic streptococci. If SSA contributes to the ability of group A Streptococcus to cause TSLS and other streptococcal diseases, then the presence of SSA or high levels of its production may be associated with strains that cause these diseases. To test this hypothesis, we screened cul- Toxin Conc. (ng/ml) Figure 4 . SSA is a potent class II-dependent T cell mitogen. SSA was prepared by Ab affinity chromatography and was identical to the material shown in Fig. 2 To explore more fully the distribution of SSA production among pathogenic streptococci, eleven strains of group A Streptococcus causing recurrent pharyngitis were screened by immunoblot. 3 of 12 strains produced SSA (Fig. 9) . Again, antibody specificity was demonstrated by the ability ofthe specific immunizing peptide (SSA 1-19) to inhibit detection of these bands.
Expression ofSSA is restricted to three streptococcal clonal lineages. Recent evidence has shown that one or a few clonal lineages ofstreptococci or staphylococci are responsible for the majority ofthe toxic shock diseases caused by these organisms ( 15, 30) . Therefore, we screened 46 additional isolates from disease episodes and organized them according to clonal lineage. Table II shows that SSA was produced by 100% of the organisms screened in only three clonal lineages: ET2, ET 14, and ET24. ET2 and ET14 lineages correspond to protein serotypes M3 and M4, respectively.
Discussion
Bacterial superantigens are thought to be causally involved in the pathogenesis of several acute and chronic human diseases (31 ) . Elucidation ofthe molecular details of superantigen-mediated T cell activation has made it possible to study specific hypotheses about the consequences of exposure to these proteins. TSLS is thought to be caused, in part, by SPE-A (3, 15) . However, the better-characterized example of a superantigen- incubated with purified T cells (1 x 106/ml) and mitomycin-treated DRl-transfected L cells (2.5 x 106/ml) for 3 dat 370C in a total of 10 ml of assay media. Viable cells were isolated on an isolymph gradient and the cells cultured overnight in assay media and 25 U/ml recombinant IL-2. Cells were harvested and the pellets stored at -70'C. Total cellular RNA was isolated, reverse transcribed into cDNA and quantitative PCR carried out as described by Choi et al. (20) . All Vfls screened and not illustrated showed no elevation over background. (32) (33) (34) . Although toxins play a critical role in the evolution of these diseases, the clone ofthe organism carrying the toxin (30) as well as a number of host factors such as the presence of circulating anti-toxin Abs are also important. Two of the major goals of this study were to definitively assign the superantigen activity we found to the molecule and to differentiate SSA, structurally and functionally, from previously characterized staphylococcal or streptococcal superantigens. Controversy exists regarding the assignment ofsuperantigen activity to several staphylococcal and streptococcal molecules, including SPE-B (35), due to possible contaminants in the preparations (36, 37) . Assignment of V(B specificities to certain superantigens has apparently also suffered from use of contaminated samples (5) . Therefore, we felt it important to purify SSA to apparent homogeneity. Sequential chromatography on RDA and Ab affinity columns was used to prepare purified SSA. The final material migrated as a 28-kD band on silver stained SDS-PAGE gel with two minor breakdown products and exhibited class II-dependent T cell mitogenic activity at concentrations < 50 ng/ml, consistent with the characteristics and potency of superantigens.
We differentiated SSA from streptococcal exotoxins, particularly SPE-A and M protein, by four independent techniques. The protein sequence data demonstrated that SSA possessed a 161  268  271  272  274  292  315  322  335  270  261  163  295  37  62  281  299  318  320  321  167  156  278  275  260  12  16 pharyngitis  pharyngitis  pharyngitis  pharyngitis  TSLSt  SID  SID  SID  SID  SID  TSLS  TSLS  TSLS  TSLS  TSLS  TSLS  TSLS  Invasive  TSLS  Invasive  TSLS  TSLS   pharyngitis   TSLS  TSLS  TSLS  TSLS  TSLS  TSLS  TSLS  TSLS  SID  SID  TSLS  TSLS  Invasive  SID  SID M3  M3  M3  M3  M3  M3  M3  M3   M3  M3  M3  M3  M3  M3   nt  nt  nt   T9/14   M4  M4  T4  M4  T4  M4  M4  M66  M18  M12  T12   nt   M3   nt  nt   1   1   2  2  2  2  2  2  2  2  2  2  2  2  2 (41 ) .
One intriguing feature ofSSA is the fact that it apparently is more similar to certain staphylococcal exotoxins than to any streptococcal pyrogenic exotoxin. The use ofRDA chromatography in our purification protocol may have provided an essential advantage in separating SSA from SPE-A and SPE-C. RDA has been shown to be an effective means of purifying virtually all staphylococcal enterotoxins (23, 24) . Given the striking resemblance ofthe NH2 terminus of SSA to SEB and SEC1,3, it is not surprising that SSA was also amenable to RDA purification. We never identified more than one peak of class II-dependent mitogenic activity in any ofthe chromatography steps subsequent to RDA, nor have any of the proteins sequenced revealed contamination with SPE-A or SPE-C. In addition, analysis of relatively crude post-RDA fractions for Vfl-specific T cell activation revealed no expansion of T cells bearing Vp gene segments reported to be responsive to SPE-A or SPE-C (1 1, 12) . Therefore, we tentatively conclude that SPE-A and SPE-C do not bind RDA, although we S. pyogenes clonal lineages has several molecular evolutionary implications. First, such striking restriction to two clonal lineages suggests that SSA may be evolutionarily new, compared to SPE-B, SPE-C, and even SPE-A, whose expression are much more widely distributed among different clones ( 15) . Second, the occurrence of SSA in two divergent streptococcal clonal lineages suggests that SSA, like the pyrogenic exotoxins, is encoded by a phage and is capable ofhorizontal transfer between different clones (28, 42) . Without a Southern blot to probe the presence or absence of the structural gene for SSA, we cannot determine if the clones that lack SSA expression do so because they lack the SSA gene or they have the gene but do not express it.
It is important to understand why isolates of two clones account for most episodes of invasive streptococcal infections ( 15 ) . One hypothesis is that additive expression of superantigens imparts a graded pathogenic phenotypes to these organisms (43) . The fact that SSA and SPE-A stimulate nonoverlapping T cell subsets might make this combination especially virulent. This possibility is made more interesting in light ofthe fact that many of the ET2 clones, one ofthe two clonal lineages that causes the majority of TSLS cases, produces both SPE-A and SSA. In this regard, it is noteworthy that Chang et al. (44) recently discovered that the clone ofS. aureus causing virtually all episodes of TSS with a urogenital focus produces enterotoxin A (SEA) as well as TSST-l . In light ofthis hypothesis, it is appropriate to ask why SSA is not produced by the other clonal lineage recovered with relatively high frequency from TSLS patients, ET 
